Alzheimer's Disease Clinical Trials in Pennsylvania

24 recruiting studies across 1 city

Browse by City

All Trials in Pennsylvania

Phase

Trial	Phase	Sponsor	Dist.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)	—	University of Southern California	<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	<1 mi
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620	Phase 3	University of Pennsylvania	<1 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia	—	GAP Innovations, PBC	<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol	—	Indiana University	<1 mi
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders	N/A	University of Michigan	<1 mi
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A	Early 1	University of Pennsylvania	<1 mi
Using the EHR to Advance Genomic Medicine Across a Diverse Health System	N/A	University of Pennsylvania	<1 mi
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)	—	University of Pennsylvania	<1 mi
Neuroinflammation Imaging in AD	Early 1	University of Pennsylvania	<1 mi
UPenn Observational Research Repository on Neurodegenerative Disease	—	University of Pennsylvania	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD	Phase 3	Annovis Bio Inc.	12 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	12 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	12 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	12 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	12 mi
ACP-204 in Adults With Alzheimer's Disease Psychosis	Phase 2/3	ACADIA Pharmaceuticals Inc.	12 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	12 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease	Phase 2	Novartis Pharmaceuticals	14 mi
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)	Phase 1	Eli Lilly and Company	14 mi
Promoting Independence With Compensatory Cognitive Rehabilitation	N/A	University of Delaware	36 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	38 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	48 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.